Skinvisible Financials
Financial Health Signals
Skinvisible passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Skinvisible generates $0.12 in operating cash flow (-$70K OCF vs -$566K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Skinvisible earns $-0.9 in operating income for every $1 of interest expense (-$590K vs $669K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Skinvisible (SKVI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Skinvisible generated $20K in revenue in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Skinvisible's EBITDA was -$569K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.7% from the prior year.
Skinvisible reported -$566K in net income in fiscal year 2024. This represents an increase of 76.3% from the prior year.
Skinvisible earned $-0.11 per diluted share (EPS) in fiscal year 2024. This represents an increase of 78.8% from the prior year.
Skinvisible held $10K in cash against $0 in long-term debt as of fiscal year 2024.
Skinvisible had 5M shares outstanding in fiscal year 2024. This represents an increase of 17.1% from the prior year.
Skinvisible's gross margin was 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.0 percentage points from the prior year.
Skinvisible's operating margin was -2948.0% in fiscal year 2024, reflecting core business profitability. This is down 496.1 percentage points from the prior year.
Skinvisible's net profit margin was -2828.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 9083.9 percentage points from the prior year.
SKVI Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $106K-22.2% | $136K-2.7% | $140K-29.6% | $199K+39.0% | $143K+15.7% | $123K-9.7% | $137K+20.4% | $114K |
| Operating Income | -$106K+22.2% | -$136K+2.6% | -$140K+29.6% | -$199K-39.3% | -$143K-15.8% | -$123K+9.8% | -$137K-20.7% | -$113K |
| Interest Expense | $144K+1.0% | $143K+1.1% | $141K-16.3% | $169K+1.2% | $167K+0.1% | $166K-0.8% | $168K0.0% | $168K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$250K+8.8% | -$274K+2.3% | -$281K-189.3% | $315K+203.7% | -$303K-4.5% | -$290K+4.4% | -$304K-5.7% | -$288K |
| EPS (Diluted) | N/A | N/A | N/A | $0.08+214.3% | $-0.07-16.7% | $-0.06+14.3% | $-0.07-16.7% | $-0.06 |
SKVI Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $134K-6.8% | $143K-4.1% | $150K-5.5% | $158K-3.0% | $163K+6.3% | $153K-5.8% | $163K-12.0% | $185K |
| Current Assets | $28K-14.0% | $33K-13.6% | $38K-8.9% | $42K+17.1% | $36K+16.9% | $31K-13.5% | $35K-33.0% | $53K |
| Cash & Equivalents | $645+437.5% | $120-99.1% | $13K+29.6% | $10K+47.9% | $7K-13.7% | $8K+811.8% | $888+21.5% | $731 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $5K0.0% | $5K+963.8% | $470-90.6% | $5K0.0% | $5K | N/A | $5K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.1M+2.4% | $9.9M+2.8% | $9.6M+2.6% | $9.4M-3.7% | $9.7M+2.9% | $9.5M+3.1% | $9.2M+3.2% | $8.9M |
| Current Liabilities | $4.8M+5.3% | $4.5M+6.3% | $4.3M+16.4% | $3.7M-9.1% | $4.0M-1.7% | $4.1M+16.6% | $3.5M+8.3% | $3.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$10.0M-2.6% | -$9.8M-2.9% | -$9.5M-2.8% | -$9.2M+3.7% | -$9.6M-2.9% | -$9.3M-3.2% | -$9.0M-3.5% | -$8.7M |
| Retained Earnings | -$40.8M-0.6% | -$40.5M-0.7% | -$40.2M-0.7% | -$39.9M+0.1% | -$40.0M-0.8% | -$39.7M-0.7% | -$39.4M-0.8% | -$39.1M |
SKVI Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $524+105.7% | -$9K+71.0% | -$32K-87.6% | -$17K+39.8% | -$28K-128.5% | -$12K-219.8% | -$4K+20.2% | -$5K |
| Capital Expenditures | -$1 | N/A | N/A | $0 | N/A | N/A | N/A | N/A |
| Free Cash Flow | $523 | N/A | N/A | -$13K | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $1 | N/A | N/A | $0 | N/A | N/A | $0-100.0% | $1 |
| Financing Cash Flow | $0 | $0-100.0% | $35K+30.6% | $27K-26.4% | $36K+85.6% | $20K+387.5% | $4K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SKVI Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0% |
| Operating Margin | -2121.1%+603.6pp | -2724.7%+72.3pp | -2797.0%+1177.8pp | -3974.9%-1121.0pp | -2853.9%-390.2pp | -2463.7%+267.1pp | -2730.8%-468.6pp | -2262.2% |
| Net Margin | -5004.9%+483.6pp | -5488.5%+131.6pp | -5620.1%-11915.5pp | 6295.4%+12364.4pp | -6069.0%-261.5pp | -5807.4%+268.4pp | -6075.8%-325.5pp | -5750.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -187.3%+4.1pp | -191.4%-3.5pp | -187.9%-386.9pp | 199.0%+385.1pp | -186.1%+3.2pp | -189.3%-2.8pp | -186.5%-31.2pp | -155.4% |
| Current Ratio | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.02 |
| Debt-to-Equity | -1.010.0 | -1.010.0 | -1.020.0 | -1.020.0 | -1.020.0 | -1.020.0 | -1.020.0 | -1.02 |
| FCF Margin | 10.5% | N/A | N/A | -250.8% | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$9.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Skinvisible's annual revenue?
Skinvisible (SKVI) reported $20K in total revenue for fiscal year 2024. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Skinvisible's revenue growing?
Skinvisible (SKVI) revenue grew by 0% year-over-year, from $20K to $20K in fiscal year 2024.
Is Skinvisible profitable?
No, Skinvisible (SKVI) reported a net income of -$566K in fiscal year 2024, with a net profit margin of -2828.3%.
What is Skinvisible's earnings per share (EPS)?
Skinvisible (SKVI) reported diluted earnings per share of $-0.11 for fiscal year 2024. This represents a 78.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Skinvisible's EBITDA?
Skinvisible (SKVI) had EBITDA of -$569K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Skinvisible's gross margin?
Skinvisible (SKVI) had a gross margin of 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Skinvisible's operating margin?
Skinvisible (SKVI) had an operating margin of -2948.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Skinvisible's net profit margin?
Skinvisible (SKVI) had a net profit margin of -2828.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Skinvisible's operating cash flow?
Skinvisible (SKVI) generated -$70K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Skinvisible's total assets?
Skinvisible (SKVI) had $158K in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does Skinvisible have outstanding?
Skinvisible (SKVI) had 5M shares outstanding as of fiscal year 2024.
What is Skinvisible's current ratio?
Skinvisible (SKVI) had a current ratio of 0.01 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Skinvisible's debt-to-equity ratio?
Skinvisible (SKVI) had a debt-to-equity ratio of -1.02 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Skinvisible's return on assets (ROA)?
Skinvisible (SKVI) had a return on assets of -357.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Skinvisible's cash runway?
Based on fiscal year 2024 data, Skinvisible (SKVI) had $10K in cash against an annual operating cash burn of $70K. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Skinvisible's debt-to-equity ratio negative or unusual?
Skinvisible (SKVI) has negative shareholder equity of -$9.2M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Skinvisible's Piotroski F-Score?
Skinvisible (SKVI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Skinvisible's earnings high quality?
Skinvisible (SKVI) has an earnings quality ratio of 0.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Skinvisible cover its interest payments?
Skinvisible (SKVI) has an interest coverage ratio of -0.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.